Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What benefits of KPV are under study?
KPV benefits under study include gut inflammation, skin inflammation, wound healing, and antimicrobial activity. See what lab and animal research has found.
Quick answer
Researchers are studying KPV for gut inflammation, skin inflammation, wound healing, and antimicrobial activity. Published research comes from cells and animals. Mice and rats with chemically induced colitis given KPV showed less colitis. KPV eye drops also left wounded rabbit corneas fully resurfaced at 60 hours. KPV is not FDA-approved and has no established labeled route, and FDA's 2026 review found no human data. KPV also falls under WADA's class of non-approved substances, prohibited at all times.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Benefits and uses researchers are exploring
Possible KPV benefits under study fall into three areas: gut inflammation, skin inflammation and wound healing, and antimicrobial activity. Published findings come from laboratory and animal research, and FDA's 2026 review found no human data1.
KPV (lysine-proline-valine) is the three-amino-acid fragment at the end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes. Researchers took interest because KPV kept alpha-MSH's anti-inflammatory effect without its pigmenting action2. KPV has since been proposed for future study in inflammatory skin and bowel disease.
Much of KPV's inflammation research has focused on the bowel.
KPV and gut inflammation
KPV has reduced chemically induced colitis, or colon inflammation, in mice and rats.
KPV entered lab-grown human gut and immune cells through PepT1, a small-peptide transporter. KPV then lowered the cells' release of inflammatory cytokines, the signaling proteins that drive inflammation. Mice with chemically induced colitis given KPV in their drinking water had less colitis and lower cytokine levels3.
Mice with ulcerative colitis received oral KPV in hyaluronic acid-coated nanoparticles inside a hydrogel. Those mice showed less gut-lining damage and lower TNF-alpha4, an inflammatory cytokine, than mice given uncoated nanoparticles. Plain KPV is unstable given rectally, so rats with chemically induced colitis received KPV in a rectal hydrogel. Those rats lost less weight and had less colon shortening5. Each result describes KPV inside that study's delivery system.
Researchers have also studied KPV in skin cells and wounds.
KPV, skin inflammation, and wound healing
KPV's skin and wound research spans lab-grown skin cells, rabbit eyes, and diabetic mice.
- Skin cells: In lab-grown human skin cells exposed to fine dust, KPV at 50 μg/mL restored cell survival and lowered IL-1β6, another inflammatory cytokine. A 3D lab-grown skin model showed less dust-induced cell death.
- Rabbit eye wounds: KPV eye drops left wounded rabbit corneas fully resurfaced at 60 hours7, while corneas given saline drops were not.
- Diabetic mouse wounds: A dressing releasing KPV and then a growth factor improved full-thickness skin wound repair8. The result reflects the combination.
Dermatology researchers call peptides like KPV promising future candidates9 for skin wounds and ulcers. Researchers have also tested KPV against bacteria and yeast.
KPV and antimicrobial activity
KPV's antimicrobial research began in lab dishes.
Tested side by side, KPV and alpha-MSH both inhibited growth of Staphylococcus aureus10, a common skin bacterium. Both peptides also reduced survival of the yeast Candida albicans. In a separate lab, alpha-MSH and a modified form of KPV showed similar activity against S. aureus and Escherichia coli11.
In rats with chemotherapy-induced mouth ulcers, a gum-applied KPV hydrogel showed antibacterial effects12 on gum ulcers infected with drug-resistant staph (MRSA). The hydrogel also contained EGCG, a plant compound with its own antibacterial activity. The result reflects the combination.
What has human research found on KPV benefits?
FDA's 2026 evidence review found no clinical studies or case reports1 of KPV in humans. The review noted KPV's effectiveness in animal wound-healing models. It also cited researchers' call for clinical studies in skin wounds and ulcers. A US registry search13 on November 4, 2026, found no registered human KPV trial.
| Research area | Laboratory and animal findings | Human research |
| Gut inflammation | Less colitis in mice and rats | No published human studies yet |
| Skin and wound healing | Skin-cell inflammation; rabbit eye and mouse wounds | No published human studies yet |
| Antimicrobial activity | Bacteria and yeast in lab dishes | No published human studies yet |
| Safety | No toxicity studies identified (FDA review) | No published human safety data yet (FDA review) |
Clinical studies would test whether these lab and animal results carry over to people. Athletes face a separate question under anti-doping rules.
KPV falls under the World Anti-Doping Agency (WADA) class of non-approved substances, prohibited at all times14. Athletes subject to drug testing can face sanctions for using KPV. Check current WADA and league rules before considering it.
Getting KPV in 2026
Superpower will offer KPV formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will assess whether KPV belongs in each person's health care. Anyone interested can join the Superpower peptide waitlist now.
KPV is not an FDA-approved drug, and access rests on an interim policy. The Department of Health and Human Services announced in October 202615 that it does not intend to take enforcement action against state-licensed pharmacies compounding certain peptides while the 503A Bulks List, which names the ingredients pharmacies may use in compounding, is finalized. The policy applies to KPV and five other peptides16, with conditions such as ingredients from FDA-registered facilities and a patient-specific prescription. A July 2026 FDA advisory committee recommendation to add KPV to the list17 preceded it; rulemaking has not concluded.